Perampanel for sporadic amyotrophic lateral sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial - Perampanel for sporadic amyotrophic lateral sclerosis (ALS)

Department of Neurology, Tokyo Medical University0 个研究点目标入组 66 人开始时间: 2017年2月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•- Patients who underwent tracheostomy. - Patients who experienced non-invasive positive pressure ventilation. - Patients whose percent-predicted forced vital capacity (%FVC) is <80%. - Patients with progressive bulbar palsy type. - Patients with cognitive impairment, severe disease in the renal, cardiovascular, or hematological system. - Patients with hepatic disease. - Patients with malignant tumor. - Pregnant women or women with a possibility of becoming pregnant. - Patients who participated in another clinical study within 12 weeks before starting the observation period. - Patients who has initiated perampanel therapy in the past or at present. - Patients who are judged to be ineligible for study entry by the investigators.

发起方

Department of Neurology, Tokyo Medical University